Ipamoralin is a specialized GH-Secretagogue and agonist of the ghrelin receptor. Its stimulation potency is comparable to GHRP6 but with fewer properties that stimulate appetite. Unlike other GH-Secretagogues, this pentapeptide doesn’t trigger the release of cortisol, acetylcholine, prolactin, and aldosterone. This unique feature has led to Ipamorelin being recognized as the first selective GH-Secretagogue.
Tesamoralin functions as a growth hormone-releasing amino acid chain in the body, though it’s not a naturally occurring amino acid chain itself. Studies have shown that it can elevate levels of IGF-1 in men by an average of 181 micrograms per liter. Its mechanism involves binding to and activating receptors in the body that respond to the natural growth hormone-releasing hormone (GHRH). In addition to boosting IGF-1, it offers other advantages such as enhancing cognitive function and reducing triglyceride levels in the bloodstream.
Recent research has demonstrated that tesamorelin can also decrease the thickness of certain blood vessel walls (carotid intima media thickness), diminish visceral adipose tissue (belly fat), and lower levels of C-reactive protein, a marker for inflammation. Notably, it appears to have minimal impact on other pituitary hormones and their functions.
Combining both Ipamorelin and Tesamorelin could potentially produce enhanced effects because each peptide activates the growth hormone axis through distinct mechanisms. Together, they work synergistically to stimulate the pituitary gland to naturally produce and release growth hormone at levels reminiscent of youth. Studies have shown that this combination leads to improved deep sleep, reduced levels of triglycerides, visceral adipose tissue (VAT), and carotid intima media thickness (cIMT), enhanced cognitive function, and overall better metabolic health.
Furthermore, studies indicate that tesamorelin may enhance memory and cognitive abilities in both healthy older adults and individuals with mild cognitive impairment who are at risk of progressing to Alzheimer’s disease.
